Atul Dandekar Sells 72,400 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 72,400 shares of the company’s stock in a transaction on Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the sale, the insider owned 10,503 shares of the company’s stock, valued at $426,001.68. The trade was a 87.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Atul Dandekar also recently made the following trade(s):

• On Tuesday, December 30th, Atul Dandekar sold 100 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.36, for a total value of $4,036.00.

Maze Therapeutics Stock Up 3.4%

Shares of Maze Therapeutics stock opened at $41.43 on Friday. Maze Therapeutics, Inc. has a 12 month low of $6.71 and a 12 month high of $43.29. The business has a fifty day simple moving average of $36.81 and a 200 day simple moving average of $24.70. The stock has a market cap of $1.99 billion and a PE ratio of -1.98.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.08.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of MAZE. CWM LLC bought a new position in shares of Maze Therapeutics during the second quarter worth about $28,000. Ameritas Investment Partners Inc. boosted its position in Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after acquiring an additional 738 shares during the last quarter. Corebridge Financial Inc. bought a new position in shares of Maze Therapeutics during the 1st quarter worth approximately $48,000. Russell Investments Group Ltd. raised its holdings in shares of Maze Therapeutics by 947.8% in the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after purchasing an additional 1,725 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Maze Therapeutics in the third quarter worth $52,000.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on MAZE. Guggenheim reissued a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a report on Friday, December 19th. HC Wainwright boosted their target price on Maze Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, December 3rd. Wedbush raised their price target on Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Wells Fargo & Company assumed coverage on Maze Therapeutics in a report on Thursday, December 4th. They set an “overweight” rating and a $55.00 price objective on the stock. Finally, Lifesci Capital raised Maze Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Three investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $43.38.

Key Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analysts have been raising ratings and targets (consensus remains a “Buy”, average PT ≈ $43.38), supporting upside expectations. Analyst Ratings/Targets
• Positive Sentiment: Several institutions have increased or initiated stakes (e.g., Vanguard, Frazier, ARCH, Marshall Wace), indicating institutional interest that can underpin the stock. Institutional Ownership Details
• Neutral Sentiment: Recent Q3/Q4 results showed an EPS beat (reported -$0.66 vs. -$0.74 consensus), which is supportive but the company remains unprofitable and clinical-stage. Earnings Summary
• Neutral Sentiment: A de‑minimis sale of 100 shares by insider Atul Dandekar (Dec. 30) is immaterial on its own. Small Form 4
• Negative Sentiment: Atul Dandekar sold 72,400 shares (~$2.94M at ~$40.56) and reduced his stake by ~87.3% — the largest and most sentiment‑negative transaction reported. Dandekar Form 4
• Negative Sentiment: CMO Harold Bernstein sold 45,000 shares (~$1.83M at ~$40.56). Large C‑suite sales can raise questions on insider conviction and add selling pressure. Bernstein Form 4
• Negative Sentiment: SVP Amy Bachrodt sold a total of 15,000 shares across Dec. 29–30 (~$606K combined; sales at ~$40.58 and ~$40.08), materially reducing her stake. Multiple insider sales may weigh on near‑term sentiment. Bachrodt Form 4

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.